Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

A new antibiotic improves treatment of parasitic infections

13.02.2004


A team of researchers from the Universitat Autònoma de Barcelona, lead by Professor Jordi Alberola, has demonstrated the efficacy and safety of a new type of antibiotic, belonging to the family called antimicrobial peptides, for treating canine leishmaniasis, which is a disease that also affects humans. It is the first time that these antibiotics have been demonstrated to be useful against parasitic diseases in real clinical situations. The antibiotic can also improve treatment of other infections, parasitic or not, in that no side effects have been observed and it is very difficult for organisms to develop resistance to them. In addition, it can also have a direct application as a drug for treating co-infection of leishmaniasis with HIV, which 10 % of people with AIDS suffer from. The findings will be published this month (February) in the magazine Antimicrobial Agents and Chemotherapy, which is the most prestigious in its field.



Twelve million people around the world are affected by leishmaniasis; 400 million more are at risk of suffering the disease and every year between 60,000 and 100,000 people die from it. Furthermore, nearly 2 million new cases are reported every year. The different forms of leishmaniasis are caused by unicellular parasites of the Leishmania genus, which are mainly spread by biting insects, similar to mosquitoes, called phlebotoms. Clinical manifestations range from slight cutaneous lesions to visceral complications that may lead to the individual’s death.

Dogs are the main reservoir of the parasite in Spain and in the rest of the Mediterranean basin, the Middle East and South America. Epidemiological studies show that around 70% of dogs in the Mediterranean area are infected. Consequently, eradication of the disease in dogs is considered to be one of the main objectives for improving human health.


A team of researchers at the Universitat Autònoma de Barcelona headed by Professor Jordi Alberola of the Department of Pharmacology, Therapeutics and Toxicology, working in collaboration with researchers at the Pompeu Fabra University and the CSIC [Spanish Council for Scientific Research] have described, for the first time, the safety and efficacy of a new type of antibiotic from the antimicrobial peptide family, little studied up until now, against canine leishmaniasis. These latter researchers had already demonstrated the efficacy in laboratory cell cultures, but the efficacy in real clinical situations against parasitic diseases had never been demonstrated.

The researchers have obtained very promising results in a preliminary study on 8 dogs affected by the disease: no adverse affects were detected; the parasitic load is decreased, and it seems to have long term effects, which could be very useful for use in therapies applied to people or animals that live in areas where medicines cannot easily be shipped to (as is the case in the principal areas affected by leishmaniasis).

One of the most direct applications of the antibiotic would be its use as a drug for treating co-infection of leishmaniasis and HIV. This new type of infection affects approximately 10 % of people who have AIDS, but in the case of the risk group made up of intravenous drug users it may be as high as 70%.

The research findings will be published this month (February) in the magazine Antimicrobial Agents and Chemotherapy, the most prestigious in its field. The findings were carried out in collaboration with Laboratorios Calier S.A and researchers at the Pompeu Fabra University and by the Spanish Council for Scientific Research (CSIC).

Octavi López Coronado | alfa
Further information:
http://www.uab.es

More articles from Health and Medicine:

nachricht Satellites, airport visibility readings shed light on troops' exposure to air pollution
09.12.2016 | Veterans Affairs Research Communications

nachricht Oxygen can wake up dormant bacteria for antibiotic attacks
08.12.2016 | Penn State

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Electron highway inside crystal

Physicists of the University of Würzburg have made an astonishing discovery in a specific type of topological insulators. The effect is due to the structure of the materials used. The researchers have now published their work in the journal Science.

Topological insulators are currently the hot topic in physics according to the newspaper Neue Zürcher Zeitung. Only a few weeks ago, their importance was...

Im Focus: Significantly more productivity in USP lasers

In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.

Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...

Im Focus: Shape matters when light meets atom

Mapping the interaction of a single atom with a single photon may inform design of quantum devices

Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

Researchers identify potentially druggable mutant p53 proteins that promote cancer growth

09.12.2016 | Life Sciences

Scientists produce a new roadmap for guiding development & conservation in the Amazon

09.12.2016 | Ecology, The Environment and Conservation

Satellites, airport visibility readings shed light on troops' exposure to air pollution

09.12.2016 | Health and Medicine

VideoLinks
B2B-VideoLinks
More VideoLinks >>>